Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clazakizumab + methotrexate
- Development stage
- Unknown
- Lead developer
- CSL Behring
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous
01
Overview
Clazakizumab + methotrexate is a combination therapy consisting of clazakizumab, a humanized monoclonal antibody that targets interleukin-6 (IL-6) cytokine, and methotrexate, a disease-modifying antirheumatic drug (DMARD). This combination has been studied for the treatment of rheumatoid arthritis (RA) in patients with an inadequate response to methotrexate alone. Clazakizumab binds to IL-6 with high affinity and blocks both classical signaling via membrane-bound IL-6R and trans-signaling via soluble IL-6R, while methotrexate further inhibits IL-6, providing complementary mechanisms of action. Clinical trials have shown that this combination significantly improves ACR20, ACR50, and ACR70 response rates compared to methotrexate monotherapy.
- Other names
- clazakizumab + methotrexateBMS-945429 + methotrexate
02
Targets
IL-6 (Interleukin 6)DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on clazakizumab + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clazakizumab + methotrexate.